Journal of Hematology & Oncology

Article	Citations
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	856
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	846
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	813
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	796
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	753
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	544
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	501
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	408
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	405
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	381
Cytokines and cancer-associated fibroblasts	374
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	346
Recent advances in targeting protein degradation for tumor immunotherapy	329
Cancer vaccines: current status and future directions	316
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	306
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	303
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	288
Landscape of biallelic DNMT3A mutant myeloid neoplasms	282
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	276
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	276
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	274
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	257
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	241
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	228
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	221

Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	220
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	214
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	210
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	205
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	203
Personalized nanovaccines for treating solid cancer metastases	193
Recent advances in therapeutic strategies for non-small cell lung cancer	193
Ferroptosis: principles and significance in health and disease	193
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	192
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	185
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	184
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	184
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	182
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies	180
Multiple myeloma risk linked to DNA damage response genes	178
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	174
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	174
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	167
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	167
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	165
Small RNA modifications: regulatory molecules and potential applications	163
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	162
Recent advances in targeted strategies for triple-negative breast cancer	158
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	154
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	151
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	150
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	148
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	148
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	147
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	146
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	145
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	144
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	139
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	137
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	136
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	135
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	134
A single-cell and spatially resolved atlas of human osteosarcomas	132
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	129
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	128
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	128
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	127
Target neutrophil heterogeneity and plasticity in cancer	127
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	120
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	119
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	119
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	117
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	116
The functional and clinical roles of liquid biopsy in patient-derived models	115
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	115

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	115
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	114
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	113
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	113
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	108
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	104
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	104
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	103
Challenges and new technologies in adoptive cell therapy	97
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	96
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	95
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	94
Gastric cancer treatment: recent progress and future perspectives	93
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	93
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	92
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	91
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	91
Targeting GPRC5D for multiple myeloma therapy	90
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	89
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	87
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality	87
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	86
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	83
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	82
Metabolic reprogramming in the tumor microenvironment of liver cancer	82
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	82
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	82
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	79
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	79
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	77
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	76
Correction: Immunosenescence: a key player in cancer development	75
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	74
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	74
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	72
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	72
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	71
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	70
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	69
Advances in targeting histone deacetylase for treatment of solid tumors	69
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	68
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	68
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	68
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	67
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	67
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	67
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	66
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	65
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	64
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	63
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	63
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies	61
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	61
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	61
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	60
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC	60
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	59
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study	58
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies	57
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study	54
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	54
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	52
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications	52
Targeting inflammation as cancer therapy	51
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	51
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy	50
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma	49
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease	49
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting	49
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting	48
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives	48
Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants	47
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease	47
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types	47
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies	46
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting	46
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy	45
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt	45
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri	44
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead	44

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2	44
CBX3 confers ferroptosis resistance during blood-borne metastasis	43
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies	43
Molecularly targeted therapy and immunotherapy in leukemias	42
Genitourinary cancers updates: highlights from ASCO 2023	42
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma	41
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy	41
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis	41
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer	40
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting	40
Novel strategies for cancer immunotherapy: counter-immunoediting therapy	38
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance	37
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	36
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial	36
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	35
Involvement of inflammasomes in tumor microenvironment and tumor therapies	34
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	34
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	34
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	34
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	34
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	34
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	33
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior	33
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	33
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated resu	32
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer	31
Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas	31
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	30
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	30
Liquid biopsy: current technology and clinical applications	30
Consensus, debate, and prospective on pancreatic cancer treatments	30
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	29
Recent advances in therapeutic strategies for triple-negative breast cancer	29
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	29
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	29
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	29
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting	28
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	28
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	28
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality	27
Lipid-based nanosystems: the next generation of cancer immune therapy	27
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	27
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	27
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer	27
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	26
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013	26
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial	26
LncRNA-encoded peptides in cancer	26
Targeting FGFR for cancer therapy	26
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial	25
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor	25
In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting	25
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting	25
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia	25
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA	25
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	24
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment	23
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	23
Recent advances in S-palmitoylation and its emerging roles in human diseases	23
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies	23
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia	23
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives	23
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors	23
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia	23
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis	22
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	22
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study	22
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase	22
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide	22
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Conso	22
Protein degradation: expanding the toolbox to restrain cancer drug resistance	22
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications	22
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia	22
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells	22
Emerging evidence and treatment paradigm of non-small cell lung cancer	22
Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets	21
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization	21
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL	21
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting	21
Correction: CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells	21
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study	21
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting	20
Clinical development of mRNA therapies against solid tumors	20
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders	20
Recent advances in targeted therapies in acute myeloid leukemia	19
Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024	19
Correction: myCAF-derived Exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment	19
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases	19
Global cancer statistics for adolescents and young adults: population based study	19
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming	19
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma	19
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias	18
Cancer associated fibroblasts in cancer development and therapy	18
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy	18
Emerging strategies to overcome resistance to third-generation EGFR inhibitors	18